Pricing

PBMs, drugmakers face off over copay accumulators

PBMs, drugmakers face off over copay accumulators

By

As with most drug pricing battles, patients yet again are caught in the crossfire.

High-profile candidates challenge marketers well in advance of launch

High-profile candidates challenge marketers well in advance of launch

By

With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.

Five things for pharma marketers to know: Thursday, March 29, 2018

Five things for pharma marketers to know: Thursday, March 29, 2018

PhRMA has released a series of new ads that blame high drug prices on cost increases to insurers and PBMs; Veterans Affairs Secretary Dr. David Shulkin has been fired; UK biotech Redx has suspended a Phase I/II trial of its cancer drug

Will PBMs take heat for high drug prices?

Will PBMs take heat for high drug prices?

PBMs began by providing a huge service to payers, but in recent years, they've begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?

ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.

ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.

By

In an unusual twist, the makers of cholesterol drug Praluent are re-pricing the treatment to align with the nonprofit's recommendation. Is industry warming to ICER?

Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?

Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?

As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.

Azar's tough assignment: 'Rocketing down' drug prices

Azar's tough assignment: 'Rocketing down' drug prices

The new HHS secretary has been given a difficult task by President Trump: bring drug prices down.

PhRMA takes Let's Talk About Cost campaign to the public

PhRMA takes Let's Talk About Cost campaign to the public

By

PhRMA wants to clear the air about drug pricing with the consumer-focused extension of the Let's Talk About Cost campaign.

Five things for pharma marketers to know: Wednesday, January 31, 2018

Five things for pharma marketers to know: Wednesday, January 31, 2018

By

CDC chief resigns; Amazon healthcare entry raises data concerns; Trump promises to make lower drug prices 'a priority'

We Save Lives While Our Critics Complain

We Save Lives While Our Critics Complain

In his first press conference as president-elect, Donald Trump insisted pharma was "getting away with murder" due to expensive drug prices.

Five things for pharma marketers to know: Tuesday, January 23, 2018

Five things for pharma marketers to know: Tuesday, January 23, 2018

By

FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW

Five things for pharma marketers to know: Friday, January 12, 2018

Five things for pharma marketers to know: Friday, January 12, 2018

By

Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds

Five things for pharma marketers to know: Thursday, January 11, 2018

Five things for pharma marketers to know: Thursday, January 11, 2018

By

Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations

Taxpayers Need to Cough up the Cash to Keep Federal Agencies Afloat

Taxpayers Need to Cough up the Cash to Keep Federal Agencies Afloat

As we continue to debate the proper size and role of government in society, cast your eyes on recent polls by Gallup and Pew that found the majority of Americans felt their income tax was fair.

Five things for pharma marketers to know: Wednesday, January 3, 2018

Five things for pharma marketers to know: Wednesday, January 3, 2018

By

Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark's genetic therapy for rare blindness costs $850,000

Five things for pharma marketers to know: Tuesday, December 19, 2017

Five things for pharma marketers to know: Tuesday, December 19, 2017

By

Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets

MM&M 2018 staff predictions: From gift bans to Google Assistant

MM&M 2018 staff predictions: From gift bans to Google Assistant

By

From gift bans to Google Assistant, POC to OPDP, MM&M staff members give their predictions on what to expect in healthcare marketing in 2018

Five things for pharma marketers to know: Thursday, December 14, 2017

Five things for pharma marketers to know: Thursday, December 14, 2017

By

Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business

Tax Bill Is Good News for Life Sciences and Marketing

Tax Bill Is Good News for Life Sciences and Marketing

Although it's a long way from the president's desk, the Tax Cut and Jobs Act of 2017 contains plenty of good news for the life sciences industry and its marketing partners.

Five things for pharma marketers to know: Tuesday, December 5, 2017

Five things for pharma marketers to know: Tuesday, December 5, 2017

By

Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds

Five things for pharma marketers to know: Friday, December 1, 2017

Five things for pharma marketers to know: Friday, December 1, 2017

By

FDA approves first Apple Watch health accessory; medical charity shared data with pharma donors; FDA approves opioid-addiction treatment

Five things for pharma marketers to know: Wednesday, November 8, 2017

Five things for pharma marketers to know: Wednesday, November 8, 2017

By

FDA to change Risk Evaluation Mitigation Strategies to prevent delayed generic approvals; Ohio rejects drug-price measure; Aetna CEO wants to improve in-person pharmacy experience

Five things for pharma marketers to know: Wednesday, November 1, 2017

Five things for pharma marketers to know: Wednesday, November 1, 2017

By

Drug industry spends nearly $50 million to fight drug-price referendum; Novartis weighs sales of generic unit; ICER to evaluate all newly approved drugs

Five things for pharma marketers to know: Thursday, October 26, 2017

Five things for pharma marketers to know: Thursday, October 26, 2017

By

Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug

Five things for pharma marketers to know: Wednesday, October 25, 2017

Five things for pharma marketers to know: Wednesday, October 25, 2017

By

FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs

10 questions for PhRMA's CEO Stephen Ubl

10 questions for PhRMA's CEO Stephen Ubl

By

Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.

Five things for pharma marketers to know: Wednesday, September 27, 2017

Five things for pharma marketers to know: Wednesday, September 27, 2017

By

AbbVie adds context to CEO's comments on drug pricing; Pandora makes a play for pharma ad dollars; shortages expected of drugs manufactured in Puerto Rico

Five things for pharma marketers to know: Tuesday, September 26, 2017

Five things for pharma marketers to know: Tuesday, September 26, 2017

By

Patient assistance nonprofit contacted in Aegerion probe; most heavily marketed drugs in Canada offer little therapeutic value; the FDA pans Duchenne drug

Five things for pharma marketers to know: Wednesday, September 13, 2017

Five things for pharma marketers to know: Wednesday, September 13, 2017

By

FDA closes pediatric study loophole; little evidence outcomes-based contracts are working; PBMs lobby against transparency efforts

Snubbing Intolerance: Frazier's Path Was Disengagement

Snubbing Intolerance: Frazier's Path Was Disengagement

By

Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.